These include studies assessing the effects of the Janus kinase 2 inhibitors, which indicated that reduced activity of the Janus kinase 2/signal transducer and activator of transcription 5 pathway, in combination with BCR-ABL inhibition by nilotinib, was able to increase apoptosis of CML stem/progenitor cells, both in vitro and in vivo 24, 25, 26, 27. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.